Literature DB >> 19515768

Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain.

Michael Schümann1, Thorsten Gantke, Elke Mühlberger.   

Abstract

Ebola virus VP35 contains a C-terminal cluster of basic amino acids required for double-stranded RNA (dsRNA) binding and inhibition of interferon regulatory factor 3 (IRF3). VP35 also blocks protein kinase R (PKR) activation; however, the responsible domain has remained undefined. Here we show that the IRF inhibitory domain of VP35 mediates the inhibition of PKR and enhances the synthesis of coexpressed proteins. In contrast to dsRNA binding and IRF inhibition, alanine substitutions of at least two basic amino acids are required to abrogate PKR inhibition and enhanced protein expression. Moreover, we show that PKR activation is not only blocked but reversed by Ebola virus infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515768      PMCID: PMC2738155          DOI: 10.1128/JVI.00523-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

2.  The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

Authors:  Zongdi Feng; Melissa Cerveny; Zhipeng Yan; Bin He
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

3.  Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA.

Authors:  Shoudong Li; Ji-Young Min; Robert M Krug; Ganes C Sen
Journal:  Virology       Date:  2006-02-08       Impact factor: 3.616

4.  Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.

Authors:  Amy L Hartman; Jason E Dover; Jonathan S Towner; Stuart T Nichol
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 5.  Pathogenesis of filoviral haemorrhagic fevers.

Authors:  Siddhartha Mahanty; Mike Bray
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

Review 6.  Structure and function of the protein kinase R.

Authors:  A J Sadler; B R G Williams
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

7.  Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity.

Authors:  Verena Krähling; David A Stein; Martin Spiegel; Friedemann Weber; Elke Mühlberger
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

8.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.

Authors:  Amy L Hartman; Brian H Bird; Jonathan S Towner; Zoi-Anna Antoniadou; Sherif R Zaki; Stuart T Nichol
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

10.  Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1.

Authors:  Kathleen C Prins; Washington B Cárdenas; Christopher F Basler
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

View more
  75 in total

1.  The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation.

Authors:  Takeshi Noda; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

2.  Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Authors:  Kathleen C Prins; Jennifer M Binning; Reed S Shabman; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Ebolavirus VP35 is a multifunctional virulence factor.

Authors:  Daisy W Leung; Kathleen C Prins; Christopher F Basler; Gaya K Amarasinghe
Journal:  Virulence       Date:  2010-11-01       Impact factor: 5.882

Review 4.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

5.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

6.  Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.

Authors:  Christopher R Kimberlin; Zachary A Bornholdt; Sheng Li; Virgil L Woods; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

7.  Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway.

Authors:  Giulia Fabozzi; Christopher S Nabel; Michael A Dolan; Nancy J Sullivan
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

8.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

9.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

10.  Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.

Authors:  Daisy W Leung; Kathleen C Prins; Dominika M Borek; Mina Farahbakhsh; JoAnn M Tufariello; Parameshwaran Ramanan; Jay C Nix; Luke A Helgeson; Zbyszek Otwinowski; Richard B Honzatko; Christopher F Basler; Gaya K Amarasinghe
Journal:  Nat Struct Mol Biol       Date:  2010-01-17       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.